No, 250 mg of mesalamine is NOT equivalent to 2.4 g of Lialda
A 250 mg dose of mesalamine is dramatically underdosed compared to 2.4 g (2400 mg) of Lialda—the latter is nearly 10 times higher and represents a standard therapeutic dose for ulcerative colitis, while 250 mg is subtherapeutic and clinically ineffective.
Understanding the Dose Discrepancy
The question appears to reflect confusion about mesalamine dosing or formulation equivalence. Let me clarify:
Lialda Dosing
- Each Lialda tablet contains 1.2 g (1200 mg) of mesalamine 1
- 2.4 g of Lialda = 2 tablets = 2400 mg of mesalamine
- This is a standard-dose mesalamine regimen (2-3 g/day) per AGA guidelines 2
The 250 mg Reference
If you're referring to a 250 mg mesalamine formulation, this likely represents:
- Pentasa 250 mg capsules (time-dependent release formulation) 2
- Olsalazine (Dipentum) 250 mg (diazo-bonded 5-ASA) 2
Critical Dosing Principles
Therapeutic Dose Ranges for Ulcerative Colitis
According to AGA guidelines 2:
- Low-dose: <2 g/day of mesalamine
- Standard-dose: 2-3 g/day of mesalamine
- High-dose: >3 g/day of mesalamine
High-dose mesalamine (>3 g/day) is superior to standard-dose, which is superior to low-dose for inducing remission 2. The evidence shows:
- High-dose: 225 fewer failures per 1000 patients vs placebo
- Standard-dose: 144 fewer failures per 1000 patients vs placebo
- Low-dose: 108 fewer failures per 1000 patients vs placebo
Formulation-Specific Equivalence
Different mesalamine formulations are NOT interchangeable on a 1:1 basis 2, 3, 4. According to the AGA Technical Review 2:
- Olsalazine 2-3 g/day = 1.6-2.4 g/day of 5-ASA equivalence
- Balsalazide 2-6.75 g/day = 0.7-2.4 g/day of 5-ASA equivalence
- Lialda (MMX mesalamine) 1.2-4.8 g/day = 1.2-4.8 g/day of 5-ASA (direct equivalence)
The Correct Conversion
If a patient is on 250 mg of a mesalamine formulation:
For Pentasa 250 mg capsules:
- To achieve 2.4 g total daily dose: 10 capsules of Pentasa 250 mg
- Pentasa has 1:1 5-ASA equivalence (0.8-3.0 g/day range) 2
For Olsalazine (Dipentum) 250 mg:
- To achieve approximately 2.4 g 5-ASA equivalence: 3-4 g of olsalazine (12-16 capsules)
- Olsalazine 2-3 g/day provides only 1.6-2.4 g/day of 5-ASA 2
To Convert TO Lialda 2.4 g:
- Simply prescribe 2 tablets of Lialda 1.2 g once daily 1
- This provides 2.4 g of mesalamine with MMX technology for delayed and extended release throughout the colon
Clinical Recommendation
If you're attempting to convert a patient from another mesalamine formulation to Lialda 2.4 g:
- Identify the current total daily 5-ASA equivalence using the conversion table 2
- Match to the appropriate Lialda dose (1.2-4.8 g/day available)
- For mild-to-moderate UC, start with at least 2.4 g/day of Lialda (standard dose) 5
- Consider 4.8 g/day for induction if moderately active disease 6
Common Pitfall
Do not assume all mesalamine formulations are equivalent milligram-for-milligram. The release mechanism, site of delivery, and prodrug conversion (for diazo-bonded formulations) significantly affect the actual 5-ASA delivered to the colon 2, 3, 4.